<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01038154</url>
  </required_header>
  <id_info>
    <org_study_id>AGIM-1</org_study_id>
    <nct_id>NCT01038154</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer</brief_title>
  <acronym>AGIM-1</acronym>
  <official_title>Randomized Controlled Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Donostia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Donostia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The survival of esophageal cancer and stomach cancer (EGC) at 5 years is less than 30%.&#xD;
      Pravastatin is a potent inhibitor of HMG-CoA reductase inhibitor that has shown increased&#xD;
      survival in patients with advanced hepatocellular carcinoma. The objective is to evaluate the&#xD;
      efficacy of treatment (increase in survival and recurrence-free period of the disease) with&#xD;
      pravastatin in patients with advanced EGC. The investigators have designed a randomized,&#xD;
      controlled and open. Advanced stage was considered for patients with T4 or N1 or M1 according&#xD;
      to the TNM classification. It has been estimated sample size per treatment arm of 73 patients&#xD;
      (146 patients in total). Randomization was done on a stratified by location (CE or CG). All&#xD;
      patients receive hatitual treatment (surgery and / or chemotherapy and / or radiotherapy and&#xD;
      / or palliative) for each of their clinical conditions. The experimental group will receive&#xD;
      one tablet of 40 mg of pravastatin orally every 24 hours (breakfast) for 2 years. There will&#xD;
      be a monthly monitoring of these patients for at least 2 years which includes an analytics.&#xD;
      Every 2 months there will be an abdominal-pelvic CT scan to assess progression and treatment&#xD;
      response.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Design: A randomized, controlled, open, parallel group study to assess the survival and&#xD;
           disease-free period or progression in patients with advanced CGE over a period of 2&#xD;
           years.&#xD;
&#xD;
        2. Under study: Patients diagnosed in histology for the first time, advanced-stage CGE and&#xD;
           fulfilling the inclusion criteria and none of the exclusion criteria proposed in the&#xD;
           Hospital Donostia (San Sebastian) and Hospital de Basurto (Bilbao) .&#xD;
&#xD;
        3. Inclusion criteria: older than 18 years, esophageal or gastric cancer histologically&#xD;
           confirmed (squamous or adenocarcinoma) for the first time, advanced stage (T4 or N1 or&#xD;
           M1) according to the fourth edition of TNM classification and signing the informed&#xD;
           consent&#xD;
&#xD;
        4. Exclusion criteria: Patients who routinely take (more than 3 days a week)&#xD;
           anti-inflammatory drugs or aspirin, patients receiving oral anticoagulants, fibrates,&#xD;
           cyclosporine and oral contraceptives, patients with hypersensitivity to pravastatin,&#xD;
           pregnant women being lactation, peripheral neuropathy grade 2 or greater, patients who&#xD;
           have been diagnosed in the previous 5 years other than skin cancer tumor that is not&#xD;
           melanoma or carcinoma in situ of cervix or bladder, patients receiving chemotherapy or&#xD;
           radiotherapy for other of tumor patients in their laboratory parameters before starting&#xD;
           the present study transaminases or alkaline phosphatase more than twice the normal&#xD;
           value, patients with platelet count less than 100.000/mm3, absolute neutrophil count&#xD;
           below 1000/mm3, or patients with evidence of bleeding diathesis or coagulopathy,&#xD;
           patients with heart failure than NYHA grade II, patients with creatinine greater than 2&#xD;
           mg / dL, patients over 75 years, asthmatics, patients with physical or mental&#xD;
           disability, patients with alcoholism or patients with diseases hereditary muscle&#xD;
&#xD;
        5. Intervention: Patients were randomized to two groups:&#xD;
&#xD;
             -  Experimental Group: You will receive one tablet of 40 mg of pravastatin Cinfa EFG,&#xD;
                orally every 24 hours (at breakfast) for 2 years.&#xD;
&#xD;
             -  Control Group: will not receive pravastatin. All patients receive the prescribed&#xD;
                treatment (surgery and / or chemotherapy and / or radiotherapy and / or palliative)&#xD;
                based on their stage and clinical situation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2009</start_date>
  <completion_date type="Anticipated">November 2012</completion_date>
  <primary_completion_date type="Anticipated">November 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>all cause mortality</measure>
    <time_frame>two years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>free time of disease recurrence</measure>
    <time_frame>two years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">146</enrollment>
  <condition>Esophageal Cancer</condition>
  <condition>Stomach Cancer</condition>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Not Receive pravastatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pravastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pravastatin</intervention_name>
    <description>Receive one tablet of 40 mg of pravastatin, orally every 24 hours (at breakfast) for 2 years.</description>
    <arm_group_label>Pravastatin</arm_group_label>
    <other_name>esophageal cancer and stomach cancer</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Over 18 years,&#xD;
&#xD;
          -  Esophageal or gastric cancer histologically confirmed (squamous or adenocarcinoma) for&#xD;
             the first time,&#xD;
&#xD;
          -  Advanced stage (T4 or N1 or M1) according to the fourth edition of TNM classification,&#xD;
&#xD;
          -  Signing the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who routinely take (more than 3 days a week) anti-inflammatory drugs or&#xD;
             aspirin,&#xD;
&#xD;
          -  Patients receiving oral anticoagulants, fibrates, cyclosporine and oral&#xD;
             contraceptives,&#xD;
&#xD;
          -  Patients with hypersensitivity to pravastatin,&#xD;
&#xD;
          -  Pregnant or lactating women,&#xD;
&#xD;
          -  Peripheral neuropathy grade 2 or greater,&#xD;
&#xD;
          -  Patients who have been diagnosed in the previous 5 years other than skin cancer tumor&#xD;
             that is not melanoma or carcinoma in situ of cervix or bladder,&#xD;
&#xD;
          -  Patients receiving chemotherapy or radiotherapy for another type of tumor,&#xD;
&#xD;
          -  Patients in their laboratory parameters before starting the present study&#xD;
             transaminases or alkaline phosphatase more than twice the normal value,&#xD;
&#xD;
          -  Patients with platelet count less than 100.000/mm3, absolute neutrophil count below&#xD;
             1000/mm3,&#xD;
&#xD;
          -  Patients with evidence of bleeding diathesis or coagulopathy,&#xD;
&#xD;
          -  Patients with heart failure than NYHA grade II,&#xD;
&#xD;
          -  Patients with creatinine greater than 2 mg / dL,&#xD;
&#xD;
          -  Patients over 75 years,&#xD;
&#xD;
          -  Asthmatics,&#xD;
&#xD;
          -  Patients with physical or mental disability,&#xD;
&#xD;
          -  Patients with alcoholism, OR&#xD;
&#xD;
          -  Patients with hereditary muscle disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luis Bujanda, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Osakidetza</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Luis Bujanda, Prof.</last_name>
    <phone>34-943007173</phone>
    <email>luis.bujanda@osakidetza.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department Gastroenterology. Hospital Donostia</name>
      <address>
        <city>San Sebastián</city>
        <state>Guipúzcoa</state>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Bujanda, Prof.</last_name>
      <phone>34-943007173</phone>
      <email>luis.bujanda@osakidetza.net</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <study_first_submitted>December 2, 2009</study_first_submitted>
  <study_first_submitted_qc>December 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2009</study_first_posted>
  <last_update_submitted>June 24, 2011</last_update_submitted>
  <last_update_submitted_qc>June 24, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2011</last_update_posted>
  <responsible_party>
    <name_title>Luis Bujanda. Department of Gastroenterology. Hospital Donostia. Osakidetza.</name_title>
    <organization>Luis Bujanda. Department of Gastroenterology. Hospital Donostia. Osakidetza.</organization>
  </responsible_party>
  <keyword>advanced esophageal cancer and stomach cancer</keyword>
  <keyword>Pravastatin</keyword>
  <keyword>Survival</keyword>
  <keyword>adverse effects</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pravastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

